2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

Autor:	Nicoletta Colombo, Robert L Coleman, Xiaohua Wu, Fatih Köse, Robert M Wenham, Alexandra Sebastianelli, Kosei Hasegawa, Emese Zsiros, Thibault De La Motte Rouge, Mariusz Bidziński, Iain McNeish, Jalid Sehouli, Jacob Korach, Philip R Debruyne, Jae-Weon Kim, Andréia C de Melo, Xuan Peng, Agata M Bogusz, Karin Yamada, Bradley J Monk
Rok vydání:	2022
Zdroj:	Ovarian cancer.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::32df62700f0bfa8aa3c964abcb3199e4 https://doi.org/10.1136/ijgc-2022-esgo.538 Zobrazit plný text záznamu